期刊文献+

肥厚型心肌病扩张期的研究现状 被引量:1

Current research situation of dilated-phase in hypertrophic cardiomyopathy
原文传递
导出
摘要 肥厚型心肌病扩张期是肥厚型心肌病的终末期改变,病理特征为心腔整体的扩大、室壁的弥漫性纤维化及小动脉管腔闭塞。肥厚型心肌病扩张期的发生与遗传因素、微循环障碍、炎症反应、氧化应激及酒精等多种因素密切相关。尽管肥厚型心肌病扩张期发病率较低,但是往往症状严重,一般药物治疗疗效不佳,通常需要心脏移植。 Summary Dilated-phase of hypertrophic cardiomyopathy (DPHCM) is the end-stage evolution of hyper- trophic cardiomyopathy, whose pathological features of DPHCM are dilated left ventricular chamber, disseminated fibrosis in ventricular wall and occluded intramural arterioles. The genetic factors, microcirculation dysfunction, inflammation and oxidative stress play critical roles in the pathological process of DPHCM. Although the occur- rence of DPHCM from classic HCM is very low, the prognosis is ominous. The conventional therapy is ineffec- tive. Cardiac transplantation is reported as the most effective treatment of DPHCM.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2013年第7期486-488,共3页 Journal of Clinical Cardiology
关键词 肥厚型心肌病 扩张期 炎症反应 微循环障碍 氧化应激 hypertrophic eardiomyopathy dilated phase inflammation microcirculation dysfunction oxida-tive stress
  • 相关文献

参考文献17

  • 1颜彦,王翔飞,王蚰南,王健生,施月芳,潘文明,黄国倩,聂振宁,葛均波.扩张性低收缩性状态——肥厚型心肌病的特殊演变[J].复旦学报(医学版),2007,34(2):198-201. 被引量:5
  • 2BIAC-INI E, COCCOLO F, FERLITO M, et al. Di lated-hypokinetic evolution of hypertrophic cardiomy opathy[J]. J AmCollCardiol,2005,46:1543-1550.
  • 3HARRIS K M, SPIRITO P, MARON M S, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy [J]. Circulation, 2006, 114:216-225.
  • 4PINAMONTI B, MERLO M, NANGAH R, et al. The progression of left ventricular systolic and diastolic dysfunctions in hypertrophic cardiomyopathy: clinical and prognostic significance [J]. J Cardiovasc Med, 2010,11: 669-677.
  • 5MELACINI r. BASSO C, ANGELINI A, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy[J]. European Heart Journal, 2010,31 :2111-2123.
  • 6FERNANDEZ A, VIGLIANO C A, CASABE J H, et al. Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment verse normal systolic function in patients with hypertrophic cardiomyopathy[J]. Am J Cardiol. 2011,108: 548- 555.
  • 7OLIVOTTO I. CECCHI F, GISTRI R. et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2006,47:1043-1048.
  • 8AQUARO G D, TODIERE G, BARISON A, et al. Myocardial blood flow and fibrosis in hypertrophic cardiomyopathy[J]. J Cardiac Fail, 2011, 17: 384-391.
  • 9张宝伟,彭文辉,王超凡,徐亚伟.迷走神经与心力衰竭[J].临床心血管病杂志,2011,27(4):249-251. 被引量:6
  • 10IWASAKI J, NAKAMURA K, MATSUBARA H, et al. Relationship between circulating levels of monocyte chemoattractant protein-I and systolic dysfunction in patients with hypertrophic cardiomyopathy[J]. Cardiovasc Pathol. 2009,18: 317 - 322.

二级参考文献42

  • 1郑茵,苏哲坦.肾素-血管紧张素-醛固酮系统基因多态性与心血管疾病关系的研究进展[J].心血管病学进展,2006,27(z1):58-62. 被引量:4
  • 2黄文艳,孙明,周宏研,裴志芳,杨天伦.血管紧张素Ⅰ转换酶基因多态性与慢性心力衰竭药物治疗效果[J].中南大学学报(医学版),2004,29(6):686-689. 被引量:5
  • 3罗礼云,彭健.肾素-血管紧张素系统及交感神经系统基因多态性与慢性心力衰竭个体化治疗[J].国际心血管病杂志,2007,34(2):122-126. 被引量:5
  • 4张安 傅信祥.肥厚型心肌病伴进行性左心室扩张[J].临床心血管病杂志,1995,11:117-118.
  • 5LINDPAINTTNER K,PFEFFER M A,KREUTZ R,et al.A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease[J].N Engl J Med,1995,332:706-711.
  • 6CROUCH M A.Pharmacotherapy implications of revised chronic heart failure guidelines[J].Consult Pharm,2006,21:576-582.
  • 7WILLENHEIMER R,VAN VELDHUISEN D J,SILKE B,et al.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) Ⅲ[J].Circulation,2005 1,112:2426-2435.
  • 8ABRAHAM M R,OLSON L J,JOYNER M J,et al.Angiotensin-converting enzyme genotype modulates pulmonaryfuncon and exercise capacity in treated patients with congestive stable heart failure[J].Circulation,2002,106:1794-1799.
  • 9CUOCO M A,PEREIRA A C,MOTA GDE F,et al.Genetic polymorphism,medical therapy and sequential cardiac function in patients with heart failure[J].Arq Bras Cardiol,2008,90:252-256.
  • 10MCNAMARA D M,HOLUBKOV R,JANOSKO K,et al.Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure[J].Circulation,2001,103:1644-1648.

共引文献23

同被引文献23

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部